In vitro comparison of cytotoxic effects of bortezomib resistant U266 myeloma cell line (U266/VELR) on combination of ibrutinib with carfilzomib and lenalidomid drugs
Abstract
Objective: Multiple myeloma is still one of the incurable hematologic cancers. It is a common problem of all hematologists to look for new combinations in this malignancy, that treatment steps are rapidly depleted.
Method: The cytotoxic activities of carfilzomib, lenalidomide and their combination with ibrutinib were evaluated using the XTT colorimetric assay on U266B1/BR cells. Cells were seeded into 96-well plates at a density of 1×104 cells per well, incubated with various concentrations of ibrutinib, carfilzomib, lenalidomide and their combinations for 24h and 48h.
Results: In our study, we found that adding ibrutinib to carfilzomib and lenalidomide combination in Bortezomib refractory myeloma cell line did not increase cytotoxicity.
Conclusions: Further clinical and experimental studies are needed to demonstrate the efficacy of ibrutinib in which many B-cell malignancy has been demonstrated.
Keywords
References
- 1. Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev. 2005;203:200-15.
- 2. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372:1430-40.
- 3. Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015;75:769-76.
- 4. Gourzones C, Bret C, Moreaux J. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma. Front Genet. 2019;10:861.
- 5. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128.
- 6. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
- 7. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
- 8. Niesvizky R, Martin TG, 3rd, Bensinger WI et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin. Cancer Res. 2013;19(8):2248-2256.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
December 31, 2019
Submission Date
December 25, 2019
Acceptance Date
December 31, 2019
Published in Issue
Year 2019 Volume: 41 Number: 4